Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 23 August 1985:
Vol. 229. no. 4715, pp. 765 - 767
DOI: 10.1126/science.4023710
Prev | Table of Contents | Next

Articles

Science, Vol 229, Issue 4715, 765-767
Copyright © 1985 by American Association for the Advancement of Science

articles

Antibody-directed urokinase: a specific fibrinolytic agent

C Bode, GR Matsueda, KY Hui, and E Haber

A specific fibrinolytic agent was synthesized by covalently coupling urokinase to a monoclonal antibody that was fibrin-specific and did not cross-react with fibrinogen. The antibody was raised against a synthetic peptide representing the seven amino-terminal residues of the beta chain of human fibrin. The urokinase-antifibrin conjugate retained the original binding specificity of the antibody and showed 100-fold increased fibrinolysis in vitro when compared to unmodified urokinase. The presence of human fibrinogen at plasma concentration did not influence these properties.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis.
S. Zaitsev, K. Danielyan, J.-C. Murciano, K. Ganguly, T. Krasik, R. P. Taylor, S. Pincus, S. Jones, D. B. Cines, and V. R. Muzykantov (2006)
Blood 108, 1895-1902
   Abstract »    Full Text »    PDF »
Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature.
B.-S. Ding, C. Gottstein, A. Grunow, A. Kuo, K. Ganguly, S. M. Albelda, D. B. Cines, and V. R. Muzykantov (2005)
Blood 106, 4191-4198
   Abstract »    Full Text »    PDF »
Antithrombotic Potency of Hirudin Is Increased in Nonhuman Primates by Fibrin Targeting.
C. Bode, S. R. Hanson, J. F. Schmedtje, E. Haber, P. Mehwald, A. B. Kelly, L. A. Harker, and M. S. Runge (1997)
Circulation 95, 800-804
   Abstract »    Full Text »
A Tissue Plasminogen Activator/P-Selectin Fusion Protein Is an Effective Thrombolytic Agent.
K. Fujise, B. M. Revelle, L. Stacy, E. L. Madison, E. T.H. Yeh, J. T. Willerson, and P. J. Beck (1997)
Circulation 95, 715-722
   Abstract »    Full Text »
Prourokinase-Annexin V Chimeras.
J. F. Tait, S. Engelhardt, C. Smith, and K. Fujikawa (1995)
J. Biol. Chem. 270, 21594-21599
   Abstract »    Full Text »    PDF »
Innovative approaches to plasminogen activator therapy.
E Haber, T Quertermous, G. Matsueda, and M. Runge (1989)
Science 243, 51-56
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)